LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,092
تعداد مقالات10,022
تعداد مشاهده مقاله27,175,160
تعداد دریافت فایل اصل مقاله7,452,418
Soltani, Ehsan, Jabbari Nooghabi, Azadeh, Jabbari Nooghabi, Mehdi, Hassanzadeh Haddad, Ehsan, Javidi Dashtbayaz, Ali. (1403). Prevalence, Clinical Features, and Consequences of the COVID-19 Pandemic in 100 Cancer Patients Operated at Omid Cancer Center-A Report from Northeast Iran. سامانه مدیریت نشریات علمی, 15(2_Supplement), -.
Ehsan Soltani; Azadeh Jabbari Nooghabi; Mehdi Jabbari Nooghabi; Ehsan Hassanzadeh Haddad; Ali Javidi Dashtbayaz. "Prevalence, Clinical Features, and Consequences of the COVID-19 Pandemic in 100 Cancer Patients Operated at Omid Cancer Center-A Report from Northeast Iran". سامانه مدیریت نشریات علمی, 15, 2_Supplement, 1403, -.
Soltani, Ehsan, Jabbari Nooghabi, Azadeh, Jabbari Nooghabi, Mehdi, Hassanzadeh Haddad, Ehsan, Javidi Dashtbayaz, Ali. (1403). 'Prevalence, Clinical Features, and Consequences of the COVID-19 Pandemic in 100 Cancer Patients Operated at Omid Cancer Center-A Report from Northeast Iran', سامانه مدیریت نشریات علمی, 15(2_Supplement), pp. -.
Soltani, Ehsan, Jabbari Nooghabi, Azadeh, Jabbari Nooghabi, Mehdi, Hassanzadeh Haddad, Ehsan, Javidi Dashtbayaz, Ali. Prevalence, Clinical Features, and Consequences of the COVID-19 Pandemic in 100 Cancer Patients Operated at Omid Cancer Center-A Report from Northeast Iran. سامانه مدیریت نشریات علمی, 1403; 15(2_Supplement): -.

Prevalence, Clinical Features, and Consequences of the COVID-19 Pandemic in 100 Cancer Patients Operated at Omid Cancer Center-A Report from Northeast Iran

Middle East Journal of Cancer
دوره 15، 2_Supplement - شماره پیاپی 58، تیر 2024    اصل مقاله (309.23 K)
نوع مقاله: Poster
نویسندگان
Ehsan Soltani1؛ Azadeh Jabbari Nooghabi* 1؛ Mehdi Jabbari Nooghabi2؛ Ehsan Hassanzadeh Haddad1؛ Ali Javidi Dashtbayaz1
1Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Statistics, Ferdowsi University of Mashhad, Mashhad, Iran
چکیده
Background: The coronavirus disease of 2019 (COVID-19) pandemic has underscored the clinical challenges in managing patients with comorbidities. Specifically, cancer patients infected by COVID-19 exhibit a significantly higher risk of developing severe complications due to their immunocompromised state, which results from both malignancy and anticancer therapies.
Method: This retrospective study, conducted from March to October 2020, evaluated postoperative morbidity and mortality among 100 cancer patients at the Omid Cancer Center in Mashhad, Iran.
Results: The median age of the patients was 53.13 ± 14.57 years; 38 (38%) were aged 60 years or older, and 47 (47%) were male (with a mean age of 58.64 ± 11.52 years). The most common malignancies were gastrointestinal (38%), breast (28%), and head and neck cancers (13%). 36 (36%) patients had received neoadjuvant anticancer therapy within 4-6 weeks before surgery. In total, 18 deaths (18%) occurred postoperatively. Among these, 2 (11.1%) patients died from COVID-19 complications during hospitalization, 1 (10%) died within the first 24 hours after discharge, and 1 (10%) died four months post-discharge due to COVID-19. Overall, only 4% of the cancer patients succumbed to the consequences of COVID-19, while 14% died due to complications associated with the cancer itself. Multiple clinical prognostic variables such as increasing age, sex, type of cancer, and treatment status (neoadjuvant or adjuvant anticancer therapy) were not linked to increased all-cause mortality.
Conclusion: The COVID-19 pandemic has led to decreased screening, diagnosis, and delays in standard cancer treatment, potentially increasing mortality and morbidity. Although cancer diagnosis and treatment should not be postponed during pandemics, infected patients require enhanced preventive care and potentially more aggressive measures.
کلیدواژه‌ها
Cancer؛ Pandemic؛ COVID-19
آمار
تعداد مشاهده مقاله: 32
تعداد دریافت فایل اصل مقاله: 109


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب